Role of Pharmacogenomics in Drug Development – An Industry ...

More documents

Recommendations

Info

We want to describe individual risk better, now we can…2001 - Human genome known and bounded2004 - 10+ Million SNP markers mapped2005 - Human LD map (HapMap)
GSK Pharmacogenetic StrategyOngoing investigations for efficacy andsafety of compounds in phase I, II, III and IVclinical trials• DNA (and other samples) collected from subjectsenrolled in GSK clinical trials• Appropriate consents - globally• ‘Collect and hold’ strategy pending results• >55,000 PGx samples• Samples from >70 countries• 99% ethics committee approval rate
Page 1 and 2: Role of Pharmacogenomics inDrug Dev
Page 3: Variation in medicine response to c
Page 7 and 8: Efficacy PGx: Opportunities• Asso
Page 9 and 10: APOE4 - a susceptibility gene varia
Page 11 and 12: ADAS-Cog Score in APOE ε4-Negative
Page 13 and 14: Rosiglitazone in ADPhase III progre
Page 15 and 16: Abacavir and Hypersensitivity (HSR)
Page 17 and 18: Abacavir HSR Prospective PGx study
Page 19 and 20: PPARγ agonist FarglitazarOedema AE
Page 21 and 22: Farglitazar oedema AE PGxSCNN1B Gen
Page 23 and 24: Ethical considerations• PGx is no

Role of Pharmacogenomics in Drug Development – An Industry ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?